# HaiHe Biopharma Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/haihe-biopharma-co

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.haihepharma.com
- Total disclosed funding: $172M
- Latest round: Series B (Jul 24, 2020)
- Investors on record: 12

## About

Founded in 2011 and based in Shanghai, China, HaiHe Biopharma Co., Ltd operates as a drug developer that focuses on the development of new drugs for oncology, metabolic diseases and other complex diseases. It has 255 employees, including 158 researchers. Jian Ding, the chairman of the Company, is an academician of the Chinese Academy of Engineering, and is the Vice President of the Chinese Pharmaceutical Society and the Chinese Society of Pharmacology. The company has 121 invention patents and participated in 3 scientific research projects of Chinese Academy of Sciences. In 2018, it established cooperation with Shanghai Institute of Pharmaceutical Sciences of the Chinese Academy of Sciences and enterprises such as Tiger Pharmaceuticals. Its production center was settled in Taizhou Pharmaceutical Hi-tech Zone, with a branch office in America in 2019. In July 2020, it raised series B funding.

The company focuses on the discovery, development, manufacture and commercialization of innovative antitumor drugs. Currently, one of its project, Haiytan was approved for marketing with another 9 products in the pipeline of research and development. Its products within include topoisomerase I inhibitors, oral c-Met selective inhibitors. It also provides services such as quality research, formulation research, pharmacological efficacy evaluation, biomarker discovery and confirmation, medical strategic planning, and clinical research.

## Funding rounds

- Series B, Jul 24, 2020, $172M — Warburg Pincus, Legend Capital, China International Capital Corporation, Shijiazhuang Pharma, CMB International Asset Management, Atlas Shanghai, Yingke Private Equity, Shanghai Chaos Investment Group, BioTrack Capital, Shanghai Sci-Tech Innovation Center Capital, Winfast Holding, ALAN AMC

## Investors

- Warburg Pincus (https://capitalatlas.ai/funds/warburg-pincus) — Series B
- Legend Capital — Series B
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series B
- Shijiazhuang Pharma — Series B
- CMB International Asset Management (https://capitalatlas.ai/funds/cmb-international-asset-management) — Series B
- Atlas Shanghai (https://capitalatlas.ai/funds/atlas-shanghai) — Series B
- Yingke Private Equity (https://capitalatlas.ai/funds/yingke-private-equity) — Series B
- Shanghai Chaos Investment Group — Series B
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series B
- Shanghai Sci-Tech Innovation Center Capital (https://capitalatlas.ai/funds/shanghai-sci-tech-innovation-center-capital) — Series B
- Winfast Holding (https://capitalatlas.ai/funds/winfast-holding) — Series B
- ALAN AMC (https://capitalatlas.ai/funds/alan-amc) — Series B